NCT04648189 2023-10-19
Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC
The Netherlands Cancer Institute
Phase 2 Withdrawn
Clinical Trials
3 trialsNCT00768131 2015-10-28
A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel
Eli Lilly and Company
Phase 2 Withdrawn
NCT00998101 2012-03-06
Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn